AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22784038 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate and emtricitabine (TDF-FTC)
Number of subjects: 1219
Study 22784038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1219
Study 19944713 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 615
Study 19944713 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 615
Study 18763437 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 593
Study 18763437 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 593
Study 16536100 — intervention group
Group type: EXPERIMENTAL
Intervention: Perineal hair cutting
Number of subjects: 458
Study 16536100 — intervention group
Group type: COMPARATOR
Intervention: Perineal shaving
Number of subjects: 458
Study 12421066 — intervention group
Group type: EXPERIMENTAL
Intervention: Parafoveal preview of target characters
Number of subjects: 0
Study 12421066 — intervention group
Group type: EXPERIMENTAL
Intervention: Parafoveal preview of graphemically similar characters
Number of subjects: 0
Study 12421066 — intervention group
Group type: COMPARATOR
Intervention: Phonological relationship between previewed radicals and subsequently viewed targets
Number of subjects: 0
Study 9932949 — intervention group
Group type: EXPERIMENTAL
Intervention: BIL transmission of tics
Number of subjects: 111
Study 9932949 — intervention group
Group type: COMPARATOR
Intervention: SP group
Number of subjects: 111
Study 9932949 — intervention group
Group type: COMPARATOR
Intervention: UNL group
Number of subjects: 111
Study 9932949 — intervention group
Group type: EXPERIMENTAL
Intervention: BIL group
Number of subjects: 111
Study 9932949 — intervention group
Group type: EXPERIMENTAL
Intervention: BIL patients
Number of subjects: 111
Study 7810529 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyacrylonitrile membrane
Number of subjects: 10
Study 7810529 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellulose triacetate membrane
Number of subjects: 10
Study 7810529 — intervention group
Group type: COMPARATOR
Intervention: Cuprophan membrane
Number of subjects: 10
Study 2318913 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose metoclopramide suppositories (150 mg)
Number of subjects: 9
Study 2318913 — intervention group
Group type: COMPARATOR
Intervention: Intravenous metoclopramide (150 mg)
Number of subjects: 9
Study 2318913 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose metoclopramide suppositories
Number of subjects: 9
Study 381860 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (234 +/- 22 mg/day)
Number of subjects: 31
Study 381860 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (25 +/- 2 mg/day)
Number of subjects: 31
Study 31471863 — intervention group
Group type: EXPERIMENTAL
Intervention: BAL101553 administered as a 48-h IV infusion at a maximum tolerated dose (MTD) of 70 mg/m2
Number of subjects: 0
Study 31471863 — intervention group
Group type: EXPERIMENTAL
Intervention: BAL101553 oral administration on Days 15–21 of cycle 2
Number of subjects: 0
Study 30548953 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption intervention in community sports clubs
Number of subjects: 0
Study 30548953 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 28988746 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfaxalone 2 mg kg−1 (A2)
Number of subjects: 10
Study 28988746 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfaxalone 1 mg kg−1 (A1)
Number of subjects: 10
Study 28988746 — intervention group
Group type: COMPARATOR
Intervention: Saline 0.1 mL kg−1 (S)
Number of subjects: 10
Study 28988746 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfaxalone 1 mg kg−1 (A1) and Alfaxalone 2 mg kg−1 (A2)
Number of subjects: 10
Study 25370598 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalizumab treatment
Number of subjects: 0
Study 23569096 — intervention group
Group type: EXPERIMENTAL
Intervention: Adult-size dishware
Number of subjects: 42
Study 23569096 — intervention group
Group type: COMPARATOR
Intervention: Child-size dishware
Number of subjects: 42
Study 21304250 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone treatment
Number of subjects: 99
Study 19835678 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT)
Number of subjects: 0
Study 19835678 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study 16923004 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanent bipolar active pacing lead, placed transcutaneously in the right ventricle and connected to an external pacing generator (n = 23, external lead group)
Number of subjects: 49
Study 16923004 — intervention group
Group type: COMPARATOR
Intervention: Conventional pacing wire/catheter (n = 26, reference group)
Number of subjects: 49
Study 15242414 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training (bicycling at 70% of maximal workload, 30 min/day, 5 days/week for 8 weeks)
Number of subjects: 8
Study 15242414 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 8
Study 15242414 — intervention group
Group type: COMPARATOR
Intervention: Control population (age-matched)
Number of subjects: 8
Study 11789085 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg micronized E2 daily
Number of subjects: 14
Study 11789085 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 9205790 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma norepinephrine (NE) levels during flashbacks in flashbackers
Number of subjects: 50
Study 9205790 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma 3-methoxy-4-hydroxyphenylglycol (MHPG) levels during flashbacks in flashbackers
Number of subjects: 50
Study 9205790 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma NE levels in subjects with persistent methamphetamine psychosis
Number of subjects: 50
Study 9205790 — intervention group
Group type: COMPARATOR
Intervention: Plasma MHPG levels in nonflashbackers
Number of subjects: 50
Study 8039273 — intervention group
Group type: COMPARATOR
Intervention: Blood pressure on entry to the trial (162/98 mmHg)
Number of subjects: 0
Study 8039273 — intervention group
Group type: COMPARATOR
Intervention: Entry blood pressure (BP)
Number of subjects: 0
Study 8039273 — intervention group
Group type: COMPARATOR
Intervention: Entry BP
Number of subjects: 0
Study 8039273 — intervention group
Group type: COMPARATOR
Intervention: Pressor effect on BP
Number of subjects: 0
Study 2459655 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine surfactant treatment
Number of subjects: 65
Study 2459655 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 65
Study 4147246 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 3‐3528, a non‐selective β‐adrenoceptor blocking drug
Number of subjects: 0
Study 4147246 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (implied as a comparison)
Number of subjects: 0
Study 31383692 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal interventions (not specified in detail)
Number of subjects: 2723
Study 31383692 — intervention group
Group type: EXPERIMENTAL
Intervention: Postnatal interventions (not specified in detail)
Number of subjects: 2723
Study 31383692 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal anthropometry and parental education (not specified in detail)
Number of subjects: 2723
Study 28425575 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (9 of 50000 IU cholecalciferol capsules for 9 weeks taken at weekly intervals)
Number of subjects: 580
Study 27979579 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (0.6 mg with weekly increase to 3.0 mg for the last week)
Number of subjects: 21
Study 27979579 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 27979579 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 21
Study 24103498 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based health insurance (CBI) scheme
Number of subjects: 0
Study 21891886 — intervention group
Group type: EXPERIMENTAL
Intervention: Light cure glass ionomer (Group I)
Number of subjects: 100
Study 21891886 — intervention group
Group type: EXPERIMENTAL
Intervention: Light cure glass ionomer (Group II)
Number of subjects: 100
Study 21891886 — intervention group
Group type: EXPERIMENTAL
Intervention: Flowable compomer (Group III)
Number of subjects: 100
Study 21891886 — intervention group
Group type: EXPERIMENTAL
Intervention: Flowable compomer (Group IV)
Number of subjects: 100
Study 19521742 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine filterwire distal protection
Number of subjects: 344
Study 19521742 — intervention group
Group type: COMPARATOR
Intervention: Standard PCI (Control)
Number of subjects: 344
Study 17920501 — intervention group
Group type: EXPERIMENTAL
Intervention: Bionator
Number of subjects: 261
Study 17920501 — intervention group
Group type: EXPERIMENTAL
Intervention: Headgear/Biteplane
Number of subjects: 261
Study 17920501 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation Group
Number of subjects: 261
Study 17920501 — intervention group
Group type: COMPARATOR
Intervention: Full orthodontic treatment (after phase 1)
Number of subjects: 261
Study 15121349 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pharmacist intervention
Number of subjects: 268
Study 11232942 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide/methotrexate/5-fluorouracil (CMF)
Number of subjects: 0
Study 11232942 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 0
Study 11232942 — intervention group
Group type: EXPERIMENTAL
Intervention: Histologic grading
Number of subjects: 0
Study 11232942 — intervention group
Group type: EXPERIMENTAL
Intervention: S-phase analysis
Number of subjects: 0
Study 9691529 — intervention group
Group type: EXPERIMENTAL
Intervention: Accent Method (AM) including voice hygiene advice plus accent exercises
Number of subjects: 0
Study 9691529 — intervention group
Group type: COMPARATOR
Intervention: Voice hygiene advice only
Number of subjects: 0
Study 7834993 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 h primed constant infusion of NaH13CO3 combined with a euglycaemic hyperinsulinaemic clamp for the last 3 h (study 1)
Number of subjects: 6
Study 7834993 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 h primed constant infusion of NaH13CO3 alone (study 2)
Number of subjects: 6
Study 7834993 — intervention group
Group type: COMPARATOR
Intervention: 6 h infusion of normal saline combined with a hyperinsulinaemic clamp for the last 3 h (study 3)
Number of subjects: 6
Study 3046537 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled albuterol
Number of subjects: 0
Study 3046537 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral theophylline
Number of subjects: 0
Study 3046537 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beta agonist
Number of subjects: 0
Study 30283403 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 2 mg BD
Number of subjects: 160
Study 30283403 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 4 mg BD
Number of subjects: 160
Study 30283403 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 8 mg BD
Number of subjects: 160
Study 30283403 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 30283403 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of melatonin combined
Number of subjects: 160
Study 30283403 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including melatonin and placebo)
Number of subjects: 160
Study 27188688 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed-gender Body Project (MG)
Number of subjects: 185
Study 27188688 — intervention group
Group type: EXPERIMENTAL
Intervention: Female-only Body Project (FO)
Number of subjects: 185
Study 27188688 — intervention group
Group type: COMPARATOR
Intervention: Waitlist Control (WL)
Number of subjects: 185
Study 24754974 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment (systemic and narrative group psychotherapy) with feedback intervention
Number of subjects: 128
Study 24754974 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment only (no feedback)
Number of subjects: 128
Study 24754974 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment with feedback intervention
Number of subjects: 128
Study 23001433 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 60
Study 23001433 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 20519875 — intervention group
Group type: EXPERIMENTAL
Intervention: miglitol
Number of subjects: 11
Study 20519875 — intervention group
Group type: COMPARATOR
Intervention: voglibose
Number of subjects: 11
Study 20519875 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 11
Study 18402652 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal tube suction for single use (LTS-D)
Number of subjects: 0
Study 18402652 — intervention group
Group type: COMPARATOR
Intervention: Bag-mask ventilation (BMV)
Number of subjects: 0
Study 16771893 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational intervention
Number of subjects: 342
Study 16771893 — intervention group
Group type: COMPARATOR
Intervention: Control group (written health risk information materials)
Number of subjects: 342
Study 14964737 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular bupivacaine
Number of subjects: 150
Study 14964737 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular lidocaine
Number of subjects: 150
Study 14964737 — intervention group
Group type: COMPARATOR
Intervention: Intravenous midazolam (0.1 mg/kg) with control (saline)
Number of subjects: 150
Study 10607768 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal haemodialysis (NHD)
Number of subjects: 10
Study 9562521 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-fed infants
Number of subjects: 430
Study 9562521 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula-fed infants
Number of subjects: 430
Study 9562521 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracking of serum lipoprotein (a) concentrations
Number of subjects: 430
Study 9562521 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest and highest lipoprotein (a) quintiles at 13 months
Number of subjects: 430
Study 9562521 — intervention group
Group type: EXPERIMENTAL
Intervention: Contribution of lipoprotein (a) cholesterol to total cholesterol
Number of subjects: 430
Study 7524921 — intervention group
Group type: EXPERIMENTAL
Intervention: Retroperitoneal lymph-node dissection (RPLND)
Number of subjects: 174
Study 7524921 — intervention group
Group type: EXPERIMENTAL
Intervention: Retroperitoneal lymph-node dissection (RPLND) without adjuvant chemotherapy
Number of subjects: 174
Study 7524921 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant chemotherapy
Number of subjects: 174
Study 7524921 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 174
Study 7524921 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival with cisplatin-based chemotherapy
Number of subjects: 174
Study 3314793 — intervention group
Group type: EXPERIMENTAL
Intervention: Wide excision
Number of subjects: 0
Study 3314793 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical mastectomy
Number of subjects: 0
Study 29194180 — intervention group
Group type: EXPERIMENTAL
Intervention: ADL retraining during PTA
Number of subjects: 104
Study 29194180 — intervention group
Group type: COMPARATOR
Intervention: No ADL retraining in PTA (treatment as usual, TAU)
Number of subjects: 104
Study 27522321 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-session, computer-assisted anxiety sensitivity intervention
Number of subjects: 104
Study 27522321 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 104
Study 25403311 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelubiprofen
Number of subjects: 145
Study 25403311 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib
Number of subjects: 145
Study 24024319 — intervention group
Group type: EXPERIMENTAL
Intervention: Dongchongxiacao (Cordyceps) treatment (n = 52)
Number of subjects: 103
Study 24024319 — intervention group
Group type: COMPARATOR
Intervention: Basic treatment (n = 51)
Number of subjects: 103
Study 21417969 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracapsular dissection (ED)
Number of subjects: 41
Study 21417969 — intervention group
Group type: COMPARATOR
Intervention: Superficial parotidectomy (SP)
Number of subjects: 41
Study 18412647 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 0.5 mg x kg(‐1)
Number of subjects: 500
Study 18412647 — intervention group
Group type: COMPARATOR
Intervention: 0.9% normal saline
Number of subjects: 500
Study 16641342 — intervention group
Group type: EXPERIMENTAL
Intervention: Reteplase plus abciximab
Number of subjects: 120
Study 16641342 — intervention group
Group type: COMPARATOR
Intervention: Urokinase plus abciximab
Number of subjects: 120
Study 12891278 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 2
Study 10781654 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol supplementation (800 I.U. per day for 12 weeks)
Number of subjects: 0
Study 8768815 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine cream during 1 week
Number of subjects: 263
Study 8768815 — intervention group
Group type: COMPARATOR
Intervention: Miconazole cream during 4 weeks
Number of subjects: 263
Study 1424849 — intervention group
Group type: EXPERIMENTAL
Intervention: Bennett Cascade 2 humidifier
Number of subjects: 0
Study 1424849 — intervention group
Group type: EXPERIMENTAL
Intervention: Fisher‐Paykel MR 460
Number of subjects: 0
Study 1424849 — intervention group
Group type: COMPARATOR
Intervention: Pall Ultipor filter (HME)
Number of subjects: 0
Study 1424849 — intervention group
Group type: EXPERIMENTAL
Intervention: Hygrobac filter (HME)
Number of subjects: 0
Study 3954590 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoulder traction device
Number of subjects: 48
Study 3954590 — intervention group
Group type: COMPARATOR
Intervention: Standard technique (manual traction)
Number of subjects: 48
Study 29705475 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot Reflexology
Number of subjects: 60
Study 28074135 — intervention group
Group type: EXPERIMENTAL
Intervention: Aclidinium 400 µg twice daily
Number of subjects: 1792
Study 28074135 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1792
Study 25459036 — intervention group
Group type: COMPARATOR
Intervention: TF-TAVR in the NRCA registry
Number of subjects: 1438
Study 22391074 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia (GA) with sphenopalatine ganglion (SPG) blocks
Number of subjects: 70
Study 22391074 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (GA) alone
Number of subjects: 70
Study 20403714 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular aneurysm repair (EVAR)
Number of subjects: 100
Study 20403714 — intervention group
Group type: COMPARATOR
Intervention: Hand-assisted laparoscopic surgery (HALS)
Number of subjects: 100
Study 18308903 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive remediation program (24 hours of computerized practice over a 12-week period and a weekly discussion group)
Number of subjects: 85
Study 18308903 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive remediation program
Number of subjects: 85
Study 18308903 — intervention group
Group type: COMPARATOR
Intervention: Computer control group (similar hours of staff and computer exposure without cognitive training exercises)
Number of subjects: 85
Study 15983466 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 2% amitriptyline
Number of subjects: 92
Study 15983466 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 1% ketamine
Number of subjects: 92
Study 15983466 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 2% amitriptyline-1% ketamine combined
Number of subjects: 92
Study 15983466 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 12406832 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (5 mg chewable tablets)
Number of subjects: 130
Study 12406832 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 10521866 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening intervention (not specified dosage or duration)
Number of subjects: 0
Study 10521866 — intervention group
Group type: COMPARATOR
Intervention: Control (not screened)
Number of subjects: 0
Study 7723712 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary dipyridamole infusion
Number of subjects: 57
Study 7723712 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 57
Study 1951907 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyloroplasty
Number of subjects: 200
Study 1951907 — intervention group
Group type: COMPARATOR
Intervention: No drainage (Control)
Number of subjects: 200
Study 7283216 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg epinephrine
Number of subjects: 32
Study 7283216 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg epinephrine
Number of subjects: 32
Study 7283216 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg epinephrine
Number of subjects: 32
Study 31725476 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) treatment
Number of subjects: 25
Study 28601691 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led transitional care intervention
Number of subjects: 199
Study 28601691 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 199
Study 26054141 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture therapy
Number of subjects: 60
Study 26054141 — intervention group
Group type: COMPARATOR
Intervention: Western medicine (budesonide nasal spray and cetirizine tablets)
Number of subjects: 60
Study 26054141 — intervention group
Group type: COMPARATOR
Intervention: Western medicine
Number of subjects: 60
Study 23783065 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg)
Number of subjects: 15
Study 23783065 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 15
Study 22137413 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 306
Study 22137413 — intervention group
Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 306